Loading patent…
AssigneeTeraclon Idf, S.L.
InventorsCarolina Elosua Portugal, Maria Teresa Mata Gonzalez, Tanya Amanda Camacho Villegas, Araceli Olguin Jimenez, Alexei Fedorovish Licea Navarro, Jorge Fernando Paniagua Solis
Estimating the term…
The present invention refers to the selection, isolation and purification of proteins belonging to variable regions named VHNAR or vNAR, originated from IgNAR-type immunoglobulins of elasmobranches with antigen receptor abilities. The clones from which they originate are named VEGFvNAR V32R and V19; and the antibodies are named V32R and V19. Their amino acid sequences and tertiary structures were elucidated, and their ability to neutralize the vascular endothelial growth factor (VEGF) activity was determined. During the development of the invention these proteins were optimized for expression in a production model of E. coli at industrial level. The invention involves the use of these antibodies in general to treat conditions related to angiogenesis or neovascularization and in particular to treat neovascularization-related ophthalmic conditions by topical administration.
An isolated anti-VEGF vNAR protein selected from the group consisting of V19 comprising the amino acid sequence of SEQ ID NO:
A medicament comprising an effective amount of an isolated anti-VEGF vNAR protein comprising the amino acid sequence of SEQ ID NO:
Dependencies are inferred from the claim text.